Men who inherit gene variants that raise GLP-1 receptor activity are more likely to have male pattern hair loss, according to a genetic analysis led by NYU Langone Health and published online July 31 in the Journal of Investigative Dermatology. The study did not follow anyone taking a GLP-1 drug. It compared inherited gene activity across public genetic databases.
Key takeaways
- Higher inherited activity of the GLP1R gene was linked to greater odds of androgenetic alopecia, the patterned thinning along the top and front of the scalp.
- This is a biological clue drawn from inherited genes, not a measured side effect rate from people on Ozempic, Wegovy or Zepbound.
What the study found
The researchers used a method called two-sample Mendelian randomization. The paper is titled “A causal effect of increased GLP1R expression on Male Pattern Hair Loss is suggested by Two-Sample Mendelian Randomization.”
The GLP1R gene controls how many GLP-1 receptor proteins the body makes. As Medical Xpress reported, the team used that gene “as an indicator of GLP-1 agonist activity,” because “more GLP1R activity means there are more GLP-1 receptor proteins.” They then checked whether the variants that push GLP1R activity up show up more often in men with androgenetic alopecia. They did.
“Our study provides the first genetic link between GLP-1 use and an increased risk of male-pattern hair loss from androgenetic alopecia, an association long suspected but until now not shown scientifically,” said senior investigator Lynn Petukhova, PhD, of NYU Grossman School of Medicine.
The analysis was limited to men.
Dr. Kumar’s take
Nearly every headline is running this as “Ozempic raises your hair loss risk.” Nobody in this study took a GLP-1 drug. Mendelian randomization uses inherited DNA variants as a stand-in for a lifetime of slightly different receptor activity. That is a very different exposure from taking a GLP-1 drug as an adult. The direction of the signal is worth taking seriously. This is not a risk estimate anyone can apply to their own prescription.
Two separate hair problems are also getting blended together. Most GLP-1 users who notice shedding describe hair coming out all over the scalp a few months after fast weight loss. That pattern is telogen effluvium, a stress response of the hair cycle, and it usually reverses. The Medical Xpress report notes that GLP-1 users “have found that hair growth resumes several months after their weight stabilizes.” Androgenetic alopecia is a different process: slow, patterned, driven by hormone sensitivity in the follicle, and progressive. This study measured the second one.
A genetic association like this is the kind of finding that tells you a receptor may be doing something in the follicle, not the kind that should change a treatment decision for diabetes or obesity.
What it means for you
If you are on a GLP-1 drug and your hair is thinning, this study is not a reason to stop. Look at the timing first. Diffuse shedding that starts two to four months after rapid weight loss usually settles once weight stabilizes, and adequate protein intake matters during that stretch.
Receding at the temples or thinning at the crown is a different problem with its own evidence-based treatments, including minoxidil, finasteride and low-level laser therapy. Petukhova raised the possibility that GLP-1 users could one day be screened for hair loss risk in advance, or given a preventive treatment such as minoxidil alongside the drug. That is a proposal for future research, not current practice.
Bring the pattern, the timing and your family history to your clinician. Those three things will sort out which kind of hair loss you actually have far better than a genetic headline will.